<DOC>
	<DOCNO>NCT00000853</DOCNO>
	<brief_summary>To expand safety information regard MN rsgp 120/HIV-1 formulate QS21 alum . To evaluate immunogenicity low dos MN rsgp 120/HIV-1 formulated QS21 alum . Studies date indicate may dose-sparing effect use QS21 . In animal study , QS21 employ adjuvant , shift dose response curve allow less antigen elicit equivalent bind antibody titer rgp120 protein . There may also acceleration course antibody response first second immunization . Although final titer response vaccine give alum QS21 appear similar 3 dos human , plateau may reach readily , low antigen dose , use QS21 adjuvant . In addition , establish use low dose antigen may elicit immune response characterize lymphoproliferation production TH1-like cytokine INF-gamma , interleukin-2 , interleukin-4 , interleukin-5 interleukin-10 .</brief_summary>
	<brief_title>A Phase I , Multicenter , Randomized , Double-Blind , Placebo-Controlled HIV-1 Vaccine Trial Evaluate Safety Immunogenicity Low Dose MN rsgp120/HIV-1 ( Genentech ) Combination With QS21 Adjuvant Alum Healthy Adults</brief_title>
	<detailed_description>Studies date indicate may dose-sparing effect use QS21 . In animal study , QS21 employ adjuvant , shift dose response curve allow less antigen elicit equivalent bind antibody titer rgp120 protein . There may also acceleration course antibody response first second immunization . Although final titer response vaccine give alum QS21 appear similar 3 dos human , plateau may reach readily , low antigen dose , use QS21 adjuvant . In addition , establish use low dose antigen may elicit immune response characterize lymphoproliferation production TH1-like cytokine INF-gamma , interleukin-2 , interleukin-4 , interleukin-5 interleukin-10 . Patients recruit screened determine eligible enrol study . Initially , 5 patient randomize combination MN rsgp 120/HIV-1 dose adjuvant , QS21 alum , along 2 control adjuvant group . An additional 10 patient randomize equally QS21 alum arm lowest dose group 2 responder define MN Vital Dye neutralization titer great equal 10 measure 2 week second vaccination . 1 additional control also randomize adjuvant group . If neither dose 2 responder , additional patient enrol . Patients receive randomly assign injection month 0 , 1 6 . Patients test DTH MN rsgp 120 12 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Inclusion Criteria Patients must : Healthy . Negative ELISA HIV . Negative Hepatitis B surface antigen . Normal urine dipstick . Normal history physical examination . Availability 18 month followup . Risk Behavior : Required : Lowerrisk sexual behavior define AVEG . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Medical psychiatric condition occupational responsibility , preclude subject compliance protocol ( e.g. , recent suicidal ideation present psychosis ) . Active syphilis . NOTE : If serology document false positive due remote ( &gt; 6 month ) treat infection , volunteer eligible ) . Active tuberculosis . NOTE : Volunteers positive PPD normal chest Xray show evidence TB require INH therapy eligible . Patients follow prior condition exclude : History immunodeficiency , chronic illness , malignancy , autoimmune disease . History cancer unless surgical excision follow sufficient observation period give reasonable assurance cure . History anaphylaxis history serious adverse reaction vaccine . History serious allergic reaction substance , require hospitalization emergent medical care . History suicide attempt past psychosis . History reaction thimerosal . Prior Medication : Excluded : History use immunosuppressive medication . Live attenuate vaccine within 60 day study . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclusionary , give least 2 week away HIV immunization . Use experimental agent within 30 day prior study . Prior receipt HIV1 vaccine placebo recipient previous HIV vaccine trial . Prior Treatment : Excluded : Receipt blood product immunoglobulin past 6 month . Risk Behavior : Excluded : Subjects identifiable higherrisk behavior HIV infection determine screen questionnaire design identify risk factor HIV infection . History injection drug use within last 12 month prior enrollment . Higher intermediaterisk sexual behavior define AVEG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>